Bone drug trial seeks to shrink hidden HIV
NCT ID NCT07216794
Summary
This study is testing whether alendronate, a medication typically used for bone health, can reduce the hidden reservoirs of HIV that persist in people on standard antiretroviral therapy. Thirty people with well-controlled HIV will be randomly assigned to receive either alendronate or a placebo pill. The main goal is to see if the drug can shrink these hidden viral reservoirs, which are a major barrier to curing HIV.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Chapel Hill (Site ID: 3201)
Chapel Hill, North Carolina, 27599, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Ohio State University (Site ID: 2301)
Columbus, Ohio, 43210, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
University of California, San Francisco HIV/AIDS (Site ID: 801)
San Francisco, California, 94110, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
University of Colorado Hospital (Site ID: 6101)
Aurora, Colorado, 80045, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
University of Pittsburgh (Site ID: 1001)
Pittsburgh, Pennsylvania, 15213, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.